Syprine, Cuprior(trientine)
Cufence, Cuprior, Syprine, Trientine (trientine) is a small molecule pharmaceutical. Trientine was first approved as Syprine on 1985-11-08. It is used to treat hepatolenticular degeneration and nervous system heavy metal poisoning in the USA. It has been approved in Europe to treat hepatolenticular degeneration.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Cuvrior, Syprine, Trientine (discontinued: Clovique, Trientine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Trientine tetrahydrochloride
Trientine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SYPRINE | Bausch Health Companies | N-019194 RX | 1985-11-08 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cuvrior | New Drug Application | 2025-06-19 |
| syprine | New Drug Application | 2020-09-01 |
| trientine hydrochloride | ANDA | 2025-10-31 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hepatolenticular degeneration | Orphanet_905 | D006527 | E83.01 |
| nervous system heavy metal poisoning | EFO_1001815 | D020260 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
20 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatolenticular degeneration | D006527 | Orphanet_905 | E83.01 | 1 | — | — | 1 | — | 2 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertrophic cardiomyopathy | D002312 | EFO_0000538 | I42.1 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Trientine |
| INN | trientine |
| Description | 2,2,2-tetramine is a polyazaalkane that is decane in which the carbon atoms at positions 1, 4, 7 and 10 are replaced by nitrogens. It has a role as a copper chelator. It is a tetramine and a polyazaalkane. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NCCNCCNCCN |
Identifiers
| PDB | — |
| CAS-ID | 112-24-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL609 |
| ChEBI ID | 39501 |
| PubChem CID | 5565 |
| DrugBank | DB06824 |
| UNII ID | SJ76Y07H5F (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Clovique – Sanofi
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,597 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
364 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use